Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a research study designed to help identify preeclampsia in pregnant women earlier, and possibly lead to better treatment for women preeclampsia.
There is a paucity of biomarkers to predict preeclampsia and for predicting the severity of preeclampsia. This study was designed to identify novel biomarkers for both the prediction of preeclampsia in previously normal pregnancies and for the prediction of the severity of preeclampsia in preeclamptic women. The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence and the investigators also plan testing for novel markers using various approaches such as proteomics, lipidomics and genomics. The targeted markers will include Aquaporin 4 (AQP4), soluble aquaporin fragments, chemokines, and halogenated fatty acids in the plasma and/or spinal fluid. Aquaporin fragments and AQP4 have been hypothesized to correlate with severe headaches which are complications of severe preeclampsia. The investigators found in their murine studies that there is a correlation between the presence of halogenated fatty acids in the plasma and elevated blood pressure in a murine model of preeclampsia. The approaches will complement the targeted analyses to identify novel markers that have not been predicted yet.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Women w/ Preeclampsia w/o Visual Disturbances or Headache | Preeclampsia Without either Visual Disturbances or Headaches Blood Pressure: >Systolic 160 or Diastolic 110 |
| |
| Women w/ Preeclampsia w/ Visual Disturbances or Headaches | Preeclampsia With either Visual Disturbances or Headaches Blood Pressure: >Systolic 160 or Diastolic 110 |
| |
| Women w/o Preeclampsia | Normal Pregnancy Blood Pressure: <140/90 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Women w/ Preeclampsia w/o Visual Disturbances or Headache | Other | Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant |
| Measure | Description | Time Frame |
|---|---|---|
| Aquaporin 4 protein fragments in maternal blood plasma | The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence | Between hospital admission and prior to epidural or combined spinal/epidural anesthesia |
| S100B protein fragments in maternal blood plasma | The investigators plan to perform targeted testing for markers that The investigators predict based on their findings or based on available published evidence | Between hospital admission and prior to epidural or combined spinal/epidural anesthesia |
| Aquaporin 4 protein fragments in cerebrospinal fluid | The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence | At the time of spinal or combined spinal/epidural anesthesia |
| S100B protein fragments in cerebrospinal fluid | The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence | At the time of spinal or combined spinal/epidural anesthesia |
| Aquaporin 4 protein fragments in cord blood and placental samples | The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence | Between delivery and 2 hours after delivery |
| S100B protein fragments in cord blood and placental samples |
| Measure | Description | Time Frame |
|---|---|---|
| Fatty acids in maternal blood | The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence | Between hospital admission and prior to epidural or combined spinal/epidural anesthesia |
| Fatty acids in cord blood and placental samples |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Women older than 20 years of age, who meet all inclusion criteria and none of the exclusion criteria, and who are willing and able to sign informed consent documentation, as well as receive a combined spinal/epidural, or a spinal anesthesia regimen.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Tekuila Carter, MD | University of Alabama at Birmingham | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | United States |
Not provided
| ID | Term |
|---|---|
| D011225 | Pre-Eclampsia |
| D004461 | Eclampsia |
| ID | Term |
|---|---|
| D046110 | Hypertension, Pregnancy-Induced |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Women w/ Preeclampsia w/ Visual Disturbances or Headaches | Other | Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant |
|
| Women w/o Preeclampsia | Other | Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant |
|
The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence
| Between delivery and 2 hours after delivery |
The investigators plan to perform targeted testing for markers that The investigators predict based on their findings or based on available published evidence |
| Between immediately post-delivery and 2 hours after delivery |
| Fatty Acids in cerebrospinal fluid | The investigators plan to perform targeted testing for markers that The investigators predict based on their findings or based on available published evidence | during epidural or combined spinal/epidural anesthesia |